UK life sciences raises $4.9bn in 2026 as round count falls to 124
UK life sciences companies raised $4.9 billion in equity funding during 2026 across just 124 rounds, according to market intelligence platform Tracxn. That compares with $5.3 billion across 294 rounds in 2025, pointing to a pronounced consolidation of capital into fewer, larger transactions rather than any broad collapse in investor appetite.
The three-year compound annual growth rate in dollar terms stands at plus 39 per cent, though the five-year figure is minus two per cent, suggesting the sector is still unwinding from the peak funding years of 2021 and 2022 rather than entering a new expansion phase.
Bigger cheques, fewer bets
The shift is most visible in median round sizes. Late-stage rounds reached a median of $67 million in 2026, up from $46 million in 2025 and roughly double the $33.3 million recorded in 2023. Series A medians climbed to $22 million, while seed-stage figures held near $1.3 million, suggesting early-stage pipelines remain active but institutional capital is concentrating at growth and expansion stages.
The single largest transaction in the period was Isomorphic Labs, the Google DeepMind spinout applying AI to drug discovery, which completed a $2.1 billion Series B in May 2026 and followed that with a reported $5.0 billion Series C in November 2026. That one company accounts for a disproportionate share of the headline dollar figure; excluding Isomorphic, the picture is considerably more subdued.
Other sizeable rounds in the 24-month window included a $411 million Series A for Verdiva Bio, a $400 million Series E for Cambridge surgical-robotics company CMR Surgical backed by Stryker, and a $310 million Series C for Oxford-based OMass Therapeutics. CellCentric, a Cambridge epigenetics oncology company, closed a $220 million Series D in May 2026 with Fidelity Investments and RA Capital among the backers.
Geography and investor patterns
London retained its position as the leading city by both company count and capital deployed, with Cambridge close behind and Oxford third. Together the three cities accounted for roughly 70 per cent of total funding by geography, a concentration that has remained broadly stable over several years and reflects the clustering of academic spinouts around the University of Cambridge, University of Oxford, and the Imperial and UCL ecosystems in London.
On the investor side, British Business Bank was the most active early-stage institutional backer over the past two years by round count, participating in ten rounds. BGF and Sofinnova Partners were also prominent at Series A and B, while IP Group led late-stage activity by number of transactions. The data underscores the continuing importance of government-backed and quasi-public vehicles in sustaining the UK pipeline at a time when some transatlantic crossover funds have pulled back from early-stage European commitments.
The acquisition market remained active, with 349 transactions recorded in total and notable recent exits including Myricx Bio to Novartis for $1.5 billion and Silence Therapeutics to Merck for $1.3 billion. The average time from first funding to acquisition was 11.4 years, consistent with the multi-decade development cycles typical of therapeutics assets.
The broader structural question for UK life sciences is whether the concentration of capital in a small number of very large rounds reflects genuine maturation of the ecosystem, with companies reaching scale and attracting crossover and strategic investors, or whether it signals a hollowing out of the mid-tier that could constrain the pipeline in future years. With round counts at their lowest level in at least five years and seed activity holding steady, the evidence is mixed.